Lucía Bailón - Concepedia

Author

Lucía Bailón

Also Known As

Jorge Arroyo Andres, José Ramón Santos, L Bailón, L Bailόn, L. Bailón, Lucia Bailon, Lucia Bailón, Lucía Bailón, Luis Uriel Lopez Bailon, Olvera, Alex

Publications

545

Citations

H-Index

Concepts

All Affiliations

Universitat Autònoma de Barcelona IrsiCaixa Universitat de Vic - Universitat Central de Catalunya Instituto de Salud Carlos III Hospital Universitari Germans Trias i Pujol

About

Lucía Bailón is an author at Universitat Autònoma de Barcelona specializing in vaccination, immunology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	162
2	Immunology	3	3	162
3	Epidemiology	1	1	10
4	Clinical Trials	1	1	10
5	Humoral Immunity	1	1	10

Lucía Bailón

Publications

281

Citations

H-Index

Page 1

	Year	Citations
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial Karin Hardt, An Vandebosch, Jerald Sadoff, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine Testing	2022	84
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial Lucía Bailón, Anuska Llano, Samandhy Cedeño, Nature Medicine VaccinationHuman RetrovirusImmunologyVaccine TrialHti Vaccines	2022	68
Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution Susana Benet, Oscar Blanch-Lombarte, Erola Ainsua‐Enrich, The Journal of Infectious Diseases	2022	36
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial Júlia Corominas, Carme Garriga, Antoni Prenafeta, The Lancet Regional Health - Europe	2023	31
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial Lucía Bailón, José Moltó, Adrián Curran, Nature Communications	2025	18
Altered T‐cell subset distribution in the viral reservoir in HIV‐1‐infected individuals with extremely low proviral DNA (LoViReTs) Cristina Gálvez, Víctor Urrea, Maria C. García-Guerrero, Journal of Internal Medicine	2022	12
HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design Ángel Bayón-Gil, María C. Puertas, Víctor Urrea, Journal of Antimicrobial Chemotherapy	2020	11
Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood Lucía Bailón, María C. Puertas, Maria C. García-Guerrero, The Journal of Infectious Diseases	2024	11
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial Júlia Corominas, Carme Garriga, Antoni Prenafeta, ImmunodeficienciesImmunologyImmunodominancePhase Iib Hh-2Vaccine Hesitancy	2022	10

Page 1